TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy
Related Posts
Bandos H, Kim S, Henry NL, Hays RD, Calsavara VF, Luu M, Gresham G, Lu KY, Irvin WJ, Suga JM, Siddique S, Cecchini RS, Rogatko[...]
Marshalek JP, Qing X, Tomassetti S. CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy. World J Oncol. 2025[...]
Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K,[...]